A Phase II, multicentre, double-blind, randomised, placebo-controlled trial to demonstrate the efficacy and safety of BP101 in patients with hypoactive sexual desire disorder.
Latest Information Update: 18 Apr 2022
At a glance
- Drugs BP 101 (Primary)
- Indications Decreased libido; Female sexual dysfunction
- Focus Therapeutic Use
- 03 Mar 2022 Planned End Date changed from 1 Feb 2022 to 1 Aug 2022.
- 24 Feb 2021 Status changed from not yet recruiting to recruiting.
- 30 Mar 2020 New trial record